Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01489046
First received: December 7, 2011
Last updated: July 14, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects


Condition Intervention Phase
HIV-1 Infection
Drug: BMS-986001
Drug: Placebo matching with BMS-986001
Drug: Efavirenz
Drug: Lamivudine
Drug: Tenofovir
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Proportion of subjects with plasma HIV-1 RNA < 50 c/mL as measured by polymerase chain reaction (PCR) analyses [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Safety as measured by numbers of subjects with Serious Adverse Events (SAEs) and numbers of subjects with Adverse Events (AEs) leading to discontinuations [ Time Frame: Week 24 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Proportion of subjects with plasma HIV-1 RNA < 50 c/mL as measured by PCR analyses [ Time Frame: Weeks 48 and 96 ] [ Designated as safety issue: No ]
  • Safety as measured by numbers of subjects with SAEs and numbers of subjects with AEs leading to discontinuation [ Time Frame: Weeks 48 and 96 ] [ Designated as safety issue: Yes ]
  • Changes from baseline in CD4+ T-cell counts [ Time Frame: Weeks 24, 48, and 96 ] [ Designated as safety issue: No ]
  • Numbers of subjects with virologic failure who exhibit genotypic substitutions in viral Ribonucleic acid (RNA) [ Time Frame: Weeks 24, 48, and 96 ] [ Designated as safety issue: No ]
  • Maximum observed concentration (Cmax) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Time of maximum observed concentration (Tmax) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Trough plasma concentration at 24 h post observed dose (Cmin) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Trough plasma concentration pre-dose (C0) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Area under the concentration-time curve in one dosing interval [AUC(0-24)] of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Average steady-state plasma concentration (Css,avg) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Enrollment: 301
Study Start Date: February 2011
Estimated Study Completion Date: July 2014
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine Drug: BMS-986001
Capsules, Oral, 100 mg, Once daily, At least 48 weeks
Drug: Placebo matching with BMS-986001
Capsules, Oral, 0 mg, Once daily, At least 48 weeks
Drug: Efavirenz
Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
Other Name: Sustiva®
Drug: Lamivudine
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Other Name: Epivir®
Experimental: Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine Drug: BMS-986001
Capsules, Oral, 200 mg, Once daily, At least 48 weeks
Drug: Placebo matching with BMS-986001
Capsules, Oral, 0 mg, Once daily, At least 48 weeks
Drug: Efavirenz
Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
Other Name: Sustiva®
Drug: Lamivudine
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Other Name: Epivir®
Experimental: Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine Drug: BMS-986001
Capsules, Oral, 400 mg, Once daily, At least 48 weeks
Drug: Efavirenz
Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
Other Name: Sustiva®
Drug: Lamivudine
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Other Name: Epivir®
Experimental: Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine Drug: Efavirenz
Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
Other Name: Sustiva®
Drug: Lamivudine
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Other Name: Epivir®
Drug: Tenofovir
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Other Name: Viread®

Detailed Description:

Double Blind through Week 24. Partially Blind (to subjects, caregivers, Investigators) through Week 48.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age, (or minimum age as determined by local regulatory or as legal requirements dictate, whichever is higher)
  • Plasma HIV-1 RNA > 5000 copies/mL
  • Antiretroviral treatment-naive; defined as no current or previous exposure to > 1 week of an antiretroviral drug
  • CD4+ T-cell count > 200 cells/mm3

Exclusion Criteria:

  • Resistance to any of the study medications [Tenofovir Disoproxil Fumarate(TDF), Efavirenz (EFV), Lamivudine (3TC)] or to HIV Protease Inhibitors (PIs)
  • Contraindications to any of the study drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01489046

  Hide Study Locations
Locations
United States, California
Uc Davis Medical Center
Sacramento, California, United States, 95817
United States, Florida
Orlando Immunology Center
Orlando, Florida, United States, 32803
Triple O Medical Services, P.A.
West Palm Beach, Florida, United States, 33401
United States, Georgia
Aids Research Consortium Of Atlanta
Atlanta, Georgia, United States, 30308
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, Maryland
Local Institution
Washingtondc, Maryland, United States, 20009
United States, Minnesota
Clinic 42 And International Travel Clinic
Minneapolis, Minnesota, United States, 55404
United States, New York
Jacobi Medical Center
Bronx, New York, United States, 10461
University At Buffalo
Buffalo, New York, United States, 14215
Local Institution
New York, New York, United States, 10011
United States, North Carolina
Local Institution
Charlotte, North Carolina, United States, 28209
United States, Pennsylvania
University Of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Local Institution
Columbia, South Carolina, United States, 29203
United States, Texas
Central Texas Clinical Research
Austin, Texas, United States, 78705
St. Hope Foundation
Bellaire, Texas, United States, 77401
North Texas Infectious Disease Consultants
Dallas, Texas, United States, 75246
Tarrant County Infectious Disease Associates
Fort Worth, Texas, United States, 76104
Therapeutic Concepts, P.A.
Houston, Texas, United States, 77004
Argentina
Local Institution
Ciudad De Buenos Aires, Buenos Aires, Argentina, C1426EGR
Australia, New South Wales
Local Institution
Darlinghurst, New South Wales, Australia, 2010
Local Institution
Liverpool, New South Wales, Australia, 1871
Australia, Victoria
Local Institution
Melbourne, Victoria, Australia, 3004
Canada, British Columbia
Local Institution
Vancouver, British Columbia, Canada, V6Z2C7
Canada, Quebec
Local Institution
Montreal, Quebec, Canada, H2L 5B1
Local Institution
Montreal, Quebec, Canada, H2L 4P9
Chile
Local Institution
Santiago, Chile, 8207257
Local Institution
Santiago, Chile, 8330744
Colombia
Local Institution
Bogota, Cundinamarca, Colombia
France
Local Institution
Lyon, France, 69004
Hungary
Local Institution
Budapest, Hungary, 1097
Mexico
Local Institution
Mexico Df, Distrito Federal, Mexico, 06470
Peru
Local Institution
Barranco, Lima, Peru, 4
Local Institution
Cercado, Lima, Peru, 1
Local Institution
San Martin De Porres, Lima, Peru, 31
Local Institution
Iquitos, Loreto, Peru
South Africa
Local Institution
Bloemfontein, Free State, South Africa, 9301
Local Institution
Johannesburg, Gauteng, South Africa, 2198
Local Institution
Soweto, Gauteng, South Africa, 2013
Local Institution
Dundee, Kwa Zulu Natal, South Africa, 3000
Local Institution
Cape Town, Western Cape, South Africa, 7925
Local Institution
Cape Town, South Africa, 7530
Local Institution
Durban, South Africa, 4001
Local Institution
Durban KZN, South Africa, 4001
Spain
Local Institution
Badalona, Spain, 08916
Local Institution
Barcelona, Spain, 08036
Local Institution
Madrid, Spain, 28040
Thailand
Local Institution
Bangkok, Thailand, 10400
Local Institution
Bangkok, Thailand, 10330
Local Institution
Bangkok, Thailand, 10700
Local Institution
Khon Kaen, Thailand, 40002
Local Institution
Nontaburi, Thailand, 11000
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01489046     History of Changes
Other Study ID Numbers: AI467-003, 2011-003329-89
Study First Received: December 7, 2011
Last Updated: July 14, 2014
Health Authority: United States: Food and Drug Administration
South Africa: Medicines Control Council
Australia: Department of Health and Ageing Therapeutic Goods Administration
Thailand: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Hungary: National Institute of Pharmacy
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Portugal: National Pharmacy and Medicines Institute
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Brazil: National Health Surveillance Agency
Chile: Instituto de Salud Pública de Chile
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Mexico: Federal Commission for Sanitary Risks Protection
Peru: General Directorate of Pharmaceuticals, Devices, and Drugs
Canada: Health Canada

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Lamivudine
Tenofovir
Tenofovir disoproxil
Efavirenz
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents

ClinicalTrials.gov processed this record on July 26, 2014